Loading
ARNT (Aryl hydrocarbon receptor nuclear translocator) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Breast cancer, Small-cell lung cancer and 1 more.
Transcription factor that functions as an obligate heterodimerisation partner for several basic helix-loop-helix PER-ARNT-SIM (bHLH-PAS) proteins. Forms heterodimers with the aryl hydrocarbon receptor (AHR) to mediate the transcriptional response to xenobiotics by binding xenobiotic response elements (XREs) or dioxin response elements (DREs) in target gene promoters. Also heterodimerises with hypoxia-inducible factor alpha subunits (HIF1A, EPAS1, NPAS1 or NPAS3) to form hypoxia-inducible transcription factors that bind hypoxia response elements (HREs) and activate genes involved in cellular and systemic responses to hypoxia, including angiogenesis, erythropoiesis, and metabolic adaptation.
Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.23, somatic mutation 0.81). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Small Cell Lung Cancer. In OnCo, 1 product record names it (Belzutifan).
In plain words · ARNT (Aryl hydrocarbon receptor nuclear translocator) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Breast cancer, Small-cell lung cancer and 1 more.
ARNT (Aryl hydrocarbon receptor nuclear translocator) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Breast cancer, Small-cell lung cancer and 1 more.
Transcription factor that functions as an obligate heterodimerisation partner for several basic helix-loop-helix PER-ARNT-SIM (bHLH-PAS) proteins.
No product in this corpus aims at ARNT yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; the 1 medicine aimed at it (Belzutifan) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA ARNT: RNA low tissue specificity; high antibody staining in 5 normal tissues; highest cancer staining glioma (5 of 11 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Breast cancer (all types), Lung cancer (all types)); approvals of single-target medicines aimed at it also list Renal cell carcinoma, Brain and spinal cord tumours (all types), Neuroendocrine tumours, Pheochromocytoma and paraganglioma (PPGL), not counted; Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas ARNT tissue; Open Targets ENSG00000143437 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Hoffman E.C. et al, Science, 1991, "Cloning of a factor required for activity of the Ah (dioxin) receptor". Source.
Sources: HGNC HGNC:700 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P27540 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000143437 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: melanoma 0.56, skin cancer 0.56, breast cancer 0.51 (GraphQL API, CC0)); IntOGen ARNT (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcription factor that functions as an obligate heterodimerisation partner for several basic helix-loop-helix PER-ARNT-SIM (bHLH-PAS) proteins. Forms heterodimers with the aryl hydrocarbon receptor (AHR) to mediate the transcriptional response to xenobiotics by binding xenobiotic response elements (XREs) or dioxin response elements (DREs) in target gene promoters. Also heterodimerises with hypoxia-inducible factor alpha subunits (HIF1A, EPAS1, NPAS1 or NPAS3) to form hypoxia-inducible transcription factors that bind hypoxia response elements (HREs) and activate genes involved in cellular and systemic responses to hypoxia, including angiogenesis, erythropoiesis, and metabolic adaptation. Plays a central role in environmental sensing and developmental and physiological regulation of gene expression. Location: Nucleus (UniProt). Locus 1q21.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Bone marrow, Breast, Caudate, Cerebral cortex, Cervix.
Medium only: breast cancer, carcinoid, endometrial cancer, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ARNT" OR ABSTRACT:"ARNT" OR TITLE:"aryl hydrocarbon receptor nuclear translocator" OR ABSTRACT:"aryl hydrocarbon receptor nuclear translocator" OR TITLE:"Aryl hydrocarbon receptor nuclear translocator" OR ABSTRACT:"Aryl hydrocarbon receptor nuclear translocator" OR TITLE:"HIF1B" OR ABSTRACT:"HIF1B" OR TITLE:"HIF-1beta" OR ABSTRACT:"HIF-1beta" OR TITLE:"bHLHe2" OR ABSTRACT:"bHLHe2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARNT, not a curated reading list.
Shares VHL / HIF oxygen sensing, Belzutifan.
Shares VHL / HIF oxygen sensing, Belzutifan.
Shares VHL / HIF oxygen sensing, IntOGen, Breast cancer (all types), Open Targets Platform.
Shares VHL / HIF oxygen sensing, Belzutifan.
Shares VHL / HIF oxygen sensing, Belzutifan.
Shares VHL / HIF oxygen sensing, Belzutifan.
Shares VHL / HIF oxygen sensing, Belzutifan.
Shares VHL / HIF oxygen sensing, Belzutifan.